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The development of visual tumor theranostic nanoparticles has become a great challenge. In this study,
D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) was conjugated to acid-sensitive cis-aconitic
anhydride-modified doxorubicin (CAD) to obtain pH-sensitive anti-tumor prodrug nanoparticles
(TCAD NPs) via self-assembling. Subsequently, the photosensitizer chlorin e6 (Ce6) was loaded into the
resulting prodrug nanoparticles to prepare a novel tumor near-infrared fluorescence imaging and
chemo–photodynamic combination therapy system (TCAD@Ce6 NPs). An accelerated release of doxo-
rubicin (DOX) and chlorin e6 (Ce6) from the TCAD@Ce6 NPs could be achieved due to the hydrolysis of
the acid-sensitive amide linker under mild acidic conditions (pH = 5.5). An in vitro experiment showed
that A549 lung cancer cells exhibited a significantly higher uptake of DOX and Ce6 by using our delivery
system than the free form of DOX and Ce6. An in vivo experiment showed that TCAD@Ce6 NPs displayed
better tumor targeting gathering through the enhanced permeability and retention (EPR) effect than free
Ce6, thus improving fluorescence imaging. Moreover, the chemo–photodynamic combination therapy of
TCAD@Ce6 NPs combined with near-infrared laser irradiation was confirmed to be capable of inducing
high apoptosis and necrosis of tumor cells (A549) in vitro and to display a significantly higher tumor
growth suppression in the A549 lung cancer-bearing mice model. Furthermore, compared with exclusive
chemotreatment (DOX) or photodynamic treatment (Ce6), our system showed enhanced therapeutic
effects both in vitro and in vivo. In conclusion, the high performance TCAD@Ce6 NPs can be used as a
promising NIR fluorescence imaging and highly effective chemo–photodynamic system for theranostics
of lung cancer, etc. in the near future.
Introduction
Lung cancer has become the no. 1 leading cause of death
worldwide and the number of lung cancer patients is rising
remarkably.1 Current cancer therapeutic methods mainly
include surgery, chemotherapy, radiotherapy and immuno-
therapy. Doxorubicin (DOX) is a highly effective chemother-
apeutic drug used to treat a wide variety of tumors such as
breast cancer, prostate cancer, brain cancer, lung cancer, etc.2,3
Furthermore, DOX with anthracycline can interact with DNA to
block gene replication and transcription.4,5 However, free DOX
is not widely used in chemotherapy due to its short half-life
and cytotoxicity to important organs such as the heart, kidney,
etc.6,7 Therefore, it is very necessary to develop novel efficient
delivery formulations of DOX to improve its clinical efficacy
and safety. To date, numerous DOX delivery systems have been
developed to improve the antitumor therapeutic efficacy of
DOX, including nanoparticles,8 intelligent micelles,4 lipo-
somes,9 and dendrimers.10 Nonetheless, chemotherapy is
accompanied by several side effects derived from its toxicity
and terrible pain, making this treatment far from ideal. Scien-
tists have already taken advantage of the combined therapy to
boost the therapeutic efficiency and simultaneously reduce the
side effects of cancer chemotherapy.11–14
In recent years, photodynamic therapy (PDT), another
effective cancer treatment method, has attracted broad attention.
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The principle of PDT treatment is that certain photo-
sensitive compounds can produce highly reactive oxygen species
(ROS) upon photoexcitation which irreversibly induce cell
apoptosis or necrosis in the targeted tissue.15 In addition,
because these photosensitizers also emit fluorescence signals
under light excitation, they can serve as a contrast agent for
tumor fluorescence imaging.16 Although PDT has been used to
treat some tumors, the potential of photosensitizers to be
widely applied to cancer therapy is still hampered by many
limitations such as their water-insolubility and low tumor tar-
geted accumulation.17,18 To overcome these drawbacks of
photosensitizers for PDT, various nanoparticle-based systems
have been developed to enhance the tumor targeting and PDT
efficacy of photosensitizers.9,19,20 Moreover, based on the
attractive tumor therapy properties of PDT, the combined treat-
ment of photodynamic and chemotherapy may optimize
cancer treatment and achieve enhanced antitumor efficiency.
Chlorin e6 (Ce6) is one of those promising photosensitizers,
and it has been approved as a tool for photodynamic diagnos-
tics in clinical application by FDA.21,22 Due to its high singlet
oxygen quantum yield and absorption/emission wavelength in
the NIR region it can induce necrosis of tumors by deeper
tissue penetration, therefore Ce6 should be an excellent photo-
sensitizer for PDT.23–26
In addition, TPGS is a water-soluble amphiphilic macro-
molecule derived from natural vitamin E, and it has been
widely used as an effective emulsifier or solubilizer.27–29 TPGS
is characterized by its bulky nature, water-solubility, and large
surface area that make it a good candidate to serve as a prom-
ising drug delivery system enhancing the solubility and bio-
availability of anticancer drugs. Actually, since FDA approved
its clinical application, as a safe drug delivery system, it is
widely used in cancer therapy with a high chemotherapeutic
efficacy and low toxic side effects.30–32
Scheme 1 Schematic illustration of the preparation of the TCAD@Ce6 NPs and their applications in vitro and in vivo. CA: cis-aconitic anhydride.
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Therefore, in order to optimize the chemotherapeutic
efficacy of doxorubicin (DOX) and improve the fluorescence
diagnosis and PDT efficacy of photosensitizer chlorin e6 (Ce6),
we firstly focus on developing D-α-tocopheryl polyethylene
glycol 1000 succinate as the carrier of the hydrophobic
chemotherapeutic agent doxorubicin (DOX) and the photo-
sensitizer chlorin e6 (Ce6) for simultaneous tumor near-infrared
fluorescence imaging and chemo–photodynamic combination
therapy. Briefly, pH-sensitive cis-aconitic anhydride (CA)-modi-
fied DOX (CAD) was firstly synthesized, then the hydroxyl term-
inal group of TPGS was bonded with the carboxyl group of cis-
aconitic anhydride (CA)-modified DOX to synthesize pH-
responsive prodrug nanoparticles (TCAD NPs) via self-assem-
bling in aqueous solution (Fig. S1† and Scheme 1). Sub-
sequently, chlorin e6 (Ce6) was loaded into the resulting
prodrug nanoparticles to prepare TCAD@Ce6 nanoparticles
(TCAD@Ce6 NPs), with TPGS as the hydrophilic shell, and
chlorin e6 and DOX as the hydrophobic core. Thanks to the
characteristic lower pH value present in tumor tissues and also
in some intracellular vesicles as endosomes and lysosomes,5,33
the acid-sensitive amide linker present in our TCAD@Ce6
nanoparticles acts as “OFF/ON” switch. Under ideal circum-
stances, our theranostic nanoparticles would not leak DOX
and would self-quench the fluorescence of Ce6 by π–π inter-
actions in blood circulation. Due to the enhanced permeability
and retention (EPR) effect, TCAD@Ce6 NPs could be gradually
accumulated into the tumor location, where TCAD@Ce6 NPs
could be activated to rapidly release DOX and Ce6 (Scheme 1)
improving tumor NIR imaging, and enhancing chemo–photo-
dynamic therapy.19 In these studies the physicochemical pro-
perties, cellular uptake efficacy, in vitro phototoxicity, in vivo
tumor targeting efficacy, and in vivo therapeutic efficacy of
TCAD@Ce6 NPs were evaluated. The results showed that the
developed acid-sensitive TCAD@Ce6 NPs displayed enhanced
anti-tumor activity, specific tumor targeting and enhanced
fluorescence imaging efficacy. Therefore, the exploited acid-
sensitive TCAD@Ce6 NPs exhibit great potential in appli-
cations such as tumor NIR fluorescence imaging and simul-
taneous chemo–photodynamic therapy in the near future.
Experimental
Materials
Doxorubicin was obtained from Dalian Meilun Biotech Co.,
Ltd (Dalian, China). D-α-tocopheryl polyethylene glycol 1000 suc-
cinate (TPGS) was purchased from Ai Keda Chemical Technol-
ogy Co., Ltd (Chengdu, China). cis-Aconitic anhydride (CA)
was received from Meryer Chemical Technology Co., Ltd
(Shanghai, China). N,N′-Dicyclohexylcarbodiimide (DCC),
N-hydroxysuccinimide (NHS), triethylamine (TEA), anhydrous
dimethyl sulfoxide (DMSO), and tetrahydrofuran (THF) were
purchased from Aladdin Reagent Co., Ltd (Shanghai, China).
3-[4,5-Dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide
(MTT) was obtained from Sigma Chemical Corporation (USA).
Annexin V-FITC/PI Apoptosis Detection Kit was purchased
from Yeasen Corporation (Shanghai, China). Hoechst 33342
and 2′,7′-dichlorofluorescein diacetate (DCFH-DA) were pur-
chased from Invitrogen Corporation (Carlsbad, CA, USA).
Chlorin e6 (Ce6) was obtained from Frontier Scientific (Utah,
USA). All other chemicals were of reagent grade. Water was
purified with a Milli-Q Plus 185 water purification system
(Millipore, Bedford, MA).
Preparation of the TCAD nanoparticles
cis-Aconitic anhydride modified doxorubicin (DOX) was pre-
pared as previously reported with some changes.34 Doxo-
rubicin hydrochloride (DOX·HCl) with twice the molar
concentration of triethylamine (TEA) was dissolved in DMSO.
The mixture was stirred overnight and light-protected at room
temperature to obtain the doxorubicin (DOX) base. cis-Aconitic
anhydride (50 mg) dissolved in 5 mL of dioxane was added
dropwise to DOX (50 mg, previously dissolved in 5 mL of pyri-
dine) under intensive stirring. The reaction mixture was stirred
overnight at 4 °C protected from light. After that, the products
were extracted five times with 10 mL chloroform and 10 mL of
5% sodium bicarbonate (aqueous solution). Then, the precipi-
tate present in the aqueous phase was removed by centrifu-
gation at 4 °C (10 000 rpm, 5 min). The pH of the supernatant
was adjusted by adding hydrochloric acid (1 N) until the pre-
cipitate was separated out (pH about 2.5–3.0). Then, the solu-
tion was stirred for another 30 min to collect the precipitate by
centrifugation at 4 °C (10 000 rpm, 10 min). The precipitate
was washed with distilled water to remove the saline solution.
The final product, referred to as “cis-aconitic anhydride-modi-
fied doxorubicin”, was dried by lyophilisation. The yield of
CAD was 50%.
Synthesis of TPGS–CAD conjugates. CAD (20 mg) was dis-
solved in 5 mL DMSO stirred for 30 min and then EDC·HCl
(27.79 mg), DMAP (2.12 mg), and DCC (11.95 mg) were added
to the CAD solution and incubated for about additional 3 h to
activate the carboxyl of CAD. TPGS (39.8 mg) was dissolved in
2 mL DMSO, added dropwise to the solution and incubated
for 24 h. Both steps were performed in the dark at 38 °C. The
insoluble byproduct (dicyclohexylurea) was removed by fil-
tration of the reaction mixture. The filtrate was separated by
dialysis (MWCO 3500) against PBS (pH 8.0) for 1 day, and then
against ultrapure water for 2 days. The final product referred to
as the “TPGS–CAD conjugate (TCAD)” was dried by lyophiliza-
tion. The yield of TCAD was 67%.
Preparation of TCAD nanoparticles. In brief, 5 mg TCAD
was dissolved in 2 mL of tetrahydrofuran (THF), then 8 mL deio-
nized water was added dropwise into the above solution. The
reaction solution was stirred at room temperature for 30 min,
whereafter the THF was removed by rotary evaporation and the
residue was resuspended in deionized water, followed by filter-
ing through a 0.45 µm pore-sized microporous membrane.
Preparation of TCAD@Ce6 nanoparticles
Chlorin e6 (Ce6) was loaded into TCAD using a simple dialysis
method. Briefly, Ce6 (2 mg) dissolved in 1 ml of 1 : 1 (v/v) THF/
DMSO was slowly added to TCAD (15 mg) dissolved in 6 mL of
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distilled water. The mixed solution was thereafter sonicated for
30 min at 100 W. Then the solution was stirred at room temp-
erature for 12 h under light-protection. The product was separ-
ated by dialysis (MWCO 3500) against 0.1 M NaHCO3 for 12 h,
and then against ultrapure water for 2 days. The Ce6 loading
capacity was estimated by the ultraviolet absorbance at 660 nm
(Fig. S2(B), ESI†) of Ce6.35 The final product was filtered
through a 0.45 µm pore-size microporous membrane.
The Entrapment Efficiency (EE) and Drug-Loading (DL)
capacity were calculated using the following equations:
EEð%Þ ¼ weight of Ce6 in nanoparticles=
weight of Ce6 fed initially  100%;
DLð%Þ ¼ weight of Ce6 in nanoparticles=weight of Ce6 in
nanoparticles and weight of carriers 100%;
Characterization
The size and morphology of the TCAD NPs and TCAD@Ce6
NPs were characterized by TEM on a JEM-2100F (JEOL, Japan).
The size and morphology of TCAD NPs were also measured by
field emission scanning electron microscopy (FESEM: Zeiss).
UV-Vis spectra were recorded with a Varian Cary 50 spectro-
photometer (Varian Inc., Palo Alto, CA, USA). PL spectra were
recorded on a Hitachi FL-4600 spectrofluorometer. DLS
(dynamic light scattering) measurements were completed
using a Nicomp 380 ZLS Zeta potential/Particle sizer (PSS
Nicomp, Santa Barbara, CA, USA). 1H NMR spectra were
acquired using a Bruker Avance-III-HD 600 MHz NMR Spectro-
meter (Bruker BioSpin Corp., Billerica, MA, USA). Fourier
transform infrared (FT-IR) spectra were recorded on a Bio-Rad
WinIR Instrument using the potassium bromide method.
Critical aggregation concentration (CAC) measurement
Pyrene was used for the fluorescence probe to determine the
CAC value of the TCAD NPs. 1 µL of pyrene acetone solution
(6 × 10−4 mol L−1) was added to 1 mL of TCAD aqueous solution
with different concentrations. The mixture was sonicated for
30 min and then was incubated for extra 12 h in the dark at
room temperature. The fluorescence intensity of the emission
wavelengths (λem) of 384 nm (I3) and 373 nm (I1) of all samples
was recorded on a Hitachi FL-4600 spectrofluorometer at
336 nm excitation wavelength and 5 nm slit width. The I3/I1
values of all samples were calculated and analyzed as a func-
tion of the logarithm of the nanoparticle concentration.
Measurement of in vitro DOX and Ce6 release
To evaluate the in vitro release profiles of DOX and Ce6 from
TCAD@Ce6 NPs, 2 mL of TCAD@Ce6 NPs (0.5 mg mL−1) was
dissolved in PBS and subsequently transferred into a mem-
brane tubing (MWCO 3500 Da). It was incubated in 80 mL PBS
at pH 7.4 (a mimicking normal physiological condition), pH
6.5 (a tumor tissue acidic microenvironment) and pH 5.5 (an
intracellular acidic microenvironment), with continuous
shaking at 100 rpm at 37 °C, respectively. At predetermined
time intervals, 1 mL of release medium was taken out, and an
equal volume of fresh PBS was returned to the system. The
accumulative amount of the released DOX and Ce6 was
detected from UV-Vis spectra at 480 nm for DOX and at
660 nm for Ce6.
TCAD@Ce6 NPs (4 µg mL−1 of Ce6 equivalents) in DMEM
medium with 10% FBS were incubated with or without A549
cells for different times at 37 °C to detect the fluorescence
intensity changes of TCAD@Ce6 NPs in tumor cells. Near-
infrared (NIR) fluorescence images were then recorded with a
Bruker In-Vivo F PRO imaging system. Moreover, the fluo-
rescence intensity changes of TCAD@Ce6 NPs were also
measured by using PL spectra before and after their incu-
bation at 37 °C in PBS (pH 5.5) for 24 h.
Cell culture
Human non-small cell lung cancer cells (A549 cells) were used
for cell studies. A549 cells were incubated in DMEM medium
with 10% FBS at 37 °C with 5% CO2. Before experiments, the
cells were pre-cultured until 75% confluence was reached.
In vitro cellular uptake and distribution of TCAD
For confocal microscopy experiments: A549 cells were plated
onto coverglass in 24-well plates at a density of 2.0 × 104 cells
per well and allowed to adhere for 24 h. Then, the culture
medium was replaced with a fresh medium containing 4 μg mL−1
free Ce6, 5.86 μg mL−1 free DOX, TCAD NPs (5.86 μg mL−1
of DOX equivalents), or the TCAD@Ce6 NPs (4 µg mL−1
of Ce6 equivalents, 5.86 μg mL−1 of DOX equivalents). After
4 h and 12 h co-incubation, the cells were washed twice with
PBS sufficiently and then fixed with 2.5% glutaraldehyde at
4 °C for 30 min. The nuclei of the cells were stained with
Hoechst 33342 at room temperature for 15 min. Confocal fluo-
rescence imaging studies were performed with a TCS SP8 con-
focal laser scanning microscope. Hoechst 33342 was excited
using the blue diode 405 nm laser and the emission was
recorded between 440 and 470 nm. Ce6 was excited at 633 nm
and the emission was collected from 650 to 800 nm. DOX was
excited at 488 nm and the emission was collected from 500 to
590 nm.
Flow cytometry (BD FACSCalibur) measurements to quan-
tify the cellular uptake: A549 cells (1.0 × 105 cells per well in
6-well plates) were cultured in medium for 24 h, and co-incu-
bated with free Ce6, free DOX, TCAD NPs or TCAD@Ce6 NPs
(with the same concentrations of confocal fluorescence
imaging studies) for 4 h and 12 h, respectively whereafter the
cells were washed with PBS and then the cells were trypsinized
and resuspended in 0.5 mL of PBS for flow cytometry measure-
ments. The fluorescence signals of Ce6 and DOX were col-
lected by using FL3-H and FL1-H channels, respectively.
Cell viability and apoptosis assay
Cellular ROS (reactive oxygen species) detection during
irradiation. The intracellular ROS generation was monitored
by staining all the cells with DCFH-DA. The A549 cells were
incubated with PBS, free Ce6 (4 μg mL−1) or TCAD@Ce6 NPs
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(equivalent Ce6 4 μg mL−1) in a six-well plate. After 24 h co-
culture, the cells were further incubated with 20 μM DCFH-DA
for 20 min and irradiated using a 633 nm He–Ne laser at a
power of 50 mW cm−2 for 3 min or not. Subsequently, the
fluorescence intensity of DCF inside the cells, which was pro-
portional to the amount of ROS produced, was detected by
flow cytometry.
In addition, the singlet oxygen sensor green (SOSG)
reagent, which is highly selective for 1O2, was employed to
measure the 1O2 generation of the TCAD@Ce6 NPs (equivalent
Ce6 4 μg mL−1) at different irradiation times at 633 nm
(50 mW cm−2) (excitation = 494 nm).
MTT assay. The dark toxicity and phototoxicity of free Ce6
and TCAD@Ce6 NPs were determined by the MTT assay of
A549 cells. Briefly, the A549 cells were seeded in a 96-well plate
at a density of 5 × 103 cells per well. After 24 h incubation, the
cells were incubated with 100 μL fresh complete medium con-
taining serial concentrations of free Ce6 (0.1–4 μg mL−1) or
TCAD@Ce6 NPs (equivalent Ce6 0.1–4 μg mL−1) or PBS
(control group). After incubation for 12 h at 37 °C in the dark,
the cells were washed twice with fresh medium, one plate was
kept in the dark to study dark toxicity, and the other plate was
irradiated using a 633 nm helium–neon (He–Ne) laser at a
power of 50 mW cm−2 for 1.5 min and 3 min, respectively.
After extra 12 h of incubation in the dark, the dark toxicity and
phototoxicity were evaluated by the MTT assay. The cell viabi-
lity was calculated according to the equation: cell viability =
(OD 570 nm of the experimental group/OD 570 nm of the
control group) × 100% and the cell viability of the control
group were denoted as 100%. According to the above protocol,
the MTT assay was also carried out to evaluate the cytotoxicity
of free DOX and TCAD NPs. The A549 cells were incubated
with 100 μL fresh complete medium containing serial concen-
trations of free DOX (0.1–6 μg mL−1) and TCAD NPs (equi-
valent DOX 0.1–6 μg mL−1) for 24 h and 48 h, respectively,
before executing the MTT assay.
Visually observation of the photodynamic therapeutic
efficacy. The A549 cells were seeded onto a 24-well plate (1 ×
104 cells per well), and then incubated for 24 h. The medium
was replaced with a fresh medium containing TCAD@Ce6 NPs
(equivalent Ce6 4 μg mL−1), or the free Ce6 (4 μg mL−1). After
12 h incubation in the dark, the A549 cells were changed to
fresh culture medium, irradiated with or without an NIR laser
(633 nm, 50 mW cm2) for 3 min. After another 12 h incubation
in the dark, the cells were washed with PBS and stained with
Calcein-AM and PI. The live cells and dead cells were stained
by using Calcein-AM and PI, respectively.
Apoptosis assay. The apoptotic and necrotic cell distri-
butions were tested according to the manufacturer’s instruc-
tion using the Annexin V-FITC/PI Apoptosis Detection Kit. The
A549 cells were exposed to free Ce6 (4 μg mL−1) or the
TCAD@Ce6 NPs (equivalent Ce6 4 μg mL−1) for 12 h. Then, the
cells were washed twice with 1 × PBS and the medium was
replaced with fresh complete culture medium, followed by
irradiation with or without a 633 nm He–Ne laser at a power of
50 mW cm−2 for 3 min. Afterward, the cells were trypsinized,
harvested, washed with 1 × PBS and resuspended in 190 μL of
binding buffer. Finally, the cells were stained with 5 μL Annexin
V and 5 μL PI in the dark at room temperature for 15 min.
300 μL of binding buffer was added to each sample before the
cells were analyzed by using a BD FACSCalibur within 30 min.
The data were analyzed by using FlowJo 7.6 software.
Tumor-targeting efficiency in tumor bearing mice
Female BALB/c-nude mice (4 weeks of age) were purchased
from Shanghai Slac Laboratory Animal Co., Ltd (Shanghai,
China). All animals received care in compliance with the
Institutional Animal Care and Use Committee of Shanghai
Jiao Tong University. The female nude mice were injected
subcutaneously in the right flank region with 150 µL of cell
suspension containing 4 × 106 A549 cells. The tumors were
allowed to grow to reach a size of ∼200 mm3 before the bio-
distribution and imaging studies. Free Ce6 or TCAD@Ce6
NPs in saline (at a dosage of Ce6 4 mg kg−1 of total mouse
body weight) were intravenously injected into the tumor-
bearing mice. Fluorescence images were obtained at 2, 4, 12,
and 24 h after injection by using a Bruker In-Vivo F PRO
imaging system (Billerica, MA, USA) (excitation: 630/20 nm;
emission: 700/30 nm; integration time: 10 s). The mice were
sacrificed, and tumors and the major organs were collected
at 24 h post-injection. The excised tumors and organs
were imaged by using the Bruker In-Vivo F PRO imaging
system with the same parameters as mentioned above.
The average fluorescence intensity of tumors and other
organs was quantified by using Bruker Molecular Imaging
Software 7.1 Version.
Photodynamic therapeutic efficacy of TCAD@Ce6 NPs in
tumor-bearing mice
In vivo chemotherapy, photodynamic and chemo–photo-
dynamic treatments were performed using A549 tumor-bearing
mice. When the tumor size reached ∼100 mm3, the mice were
randomized into six groups of 3 animals per group. (1) PBS
(150 μL) without a laser, (2) PBS (150 μL) with a laser,
(3) free Ce6 (4 mg kg−1) upon laser irradiation, (4) free DOX
(5.86 mg kg−1), (5) TCAD NPs (equivalent DOX 5.86 mg kg−1)
and (6) TCAD@Ce6 NPs (4 mg kg−1 of Ce6 equivalents,
5.86 mg kg−1 of DOX equivalents) with laser irradiation were
injected into the tail vein, respectively. For the irradiated
groups, a 633 nm He–Ne laser (50 mW cm−2, 30 min) was used
after 12 h of intravenous injection. The tumor images of A549
tumor-bearing mice were taken at the day before the tumors
were exposed to the irradiation (0 day) and at 12 h (1 day),
4 days (4 day), 14 days (14 day) after irradiation, respectively.
The tumor size and body weight were measured by using a
caliper and an electronic balance every three days after treat-
ment, respectively. Tumor volume = a × (b)2 × 1/2, where a and
b represent the maximum length and the minimal width of
tumors, respectively. On day 18, the mice treated with
TCAD@Ce6 NPs were sacrificed. The heart, liver, spleen, lung,
and kidney were excised and further investigated after H&E
staining to monitor the morphological features of each organ.
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Results and discussion
Synthesis and characterization
To provide the prepared delivery system with acid-sensitive pro-
perties for tumor specific drug release, acid-sensitive cis-aconi-
tic anhydride-modified DOX (CAD) was firstly prepared
through the ring-opening reaction4 (Fig. S1, ESI†). As shown in
the 1H NMR spectra (Fig. 1A – DOX), the peak at about
7.9 ppm belongs to the protons of the anthracene moiety of
DOX. After cis-aconitic anhydride modification, additional
signals at 6.1 and 6.4 ppm appeared, attributed to the protons
(CH–COO–) of the cis-aconitic anhydride linkages in the struc-
ture of cis-DOX (Fig. 1A – CAD). Surface TPGS modification is
demonstrated to further improve the cellular uptake and
increase the half-life as well as the therapeutic effects of the
drug.36 Therefore, in this study we modified CAD with TPGS by
the ester linkage (Fig. S1, ESI†). 1H NMR spectra of TPGS and
TCAD displayed an intense signal at around 2.0 ppm, attribu-
ted to the protons of succinyl methylene (Fig. 1B). Also, the
characteristic peak of TPGS at 3.5 ppm belonging to the
methylene protons of the mPEG part can be observed in both
spectra of TPGS and TCAD (Fig. 1B). Because of the relatively
small molecular weight of CAD, we could only see the much
weaker intensity of CAD characteristic proton signals at
around 8.0, 13.2, and 14.0 ppm (Fig. 1B, insert) compared with
that of TPGS. FT-IR spectra were further used to confirm the
structure of these formed compounds as shown in Fig. 1C.
The signals that appeared at around 1548 cm−1 (amide II) in
CAD were assigned to the characteristic signals of the formed
amide bond. After the TPGS modification, the new absorption
bands at 1111 cm−1 were attributed to the stretching modes of
–CH2–O–CH2– of the TPGS, while the typical absorption bands
at 3440 and 1633 cm−1 were associated with the stretch of the
phenolic hydroxyl group and amide I of CAD. Moreover, the
small peaks at 1695 and 1584 cm−1 indicated the formation of
the ester group between TPGS and CAD (Fig. 1D). The TCAD
was also characterized by ultraviolet-visible spectrophotometry
(UV-Vis) (Fig. S2(A), ESI†). All of the above experiments con-
firmed the successful synthesis of TCAD. In water, the amphi-
philicity character of the TCAD allows it to self-assemble into
nanoparticles, with insoluble DOX as the hydrophobic core
and TPGS as the hydrophilic shell. To perform tumor targeting
fluorescence imaging and chemo–photodynamic combination
therapy, chlorin e6 (Ce6) was loaded into the TCAD NPs to
form the TCAD@Ce6 NPs via the self-assembly process. The
loading efficacy, encapsulation efficiency and hydrodynamic
diameter were altered with the change of D/P ratios (Table 1).
To obtain high Ce6 loading ratios and reduce the waste of the
Ce6, the D/P ratio of 20% was selected for further studies. The
loading efficacy determined by UV-Vis spectroscopy was about
14.89%. The absorbance spectra of TCAD NPs, free Ce6 and
TCAD@Ce6 NPs were measured by UV-Vis spectroscopy.
TCAD@Ce6 NPs have a characteristic absorption peak of DOX
at 480 nm and a bathochromic absorption peak of Ce6 at
659 nm (Fig. S2(B), ESI†). The bathochromic shift of the
absorption peak of Ce6 may respond to the changes of the Ce6
Fig. 1 1H NMR and FT-IR spectra of DOX (DMSO-d6), CAD (DMSO-d6), TPGS (CDCl3), and TCAD (CDCl3).
Table 1 Characteristics of TCAD@Ce6 NPs after Ce6 loading
D/P ratioa EE% DL (%) Diameterb (nm)
1 : 10 98.50% 8.96% 157.20 ± 3.1
1 : 20 85.25% 14.89% 160.00 ± 1.6
a D/P ratio = weight of Ce6/weight of TCAD. bMeasured using dynamic
light scattering (DLS), data represent mean ± SD, n = 3.
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environment.37 As a result, the Ce6 was successfully encapsu-
lated into the TCAD NPs.
The hydrodynamic diameter of TCAD NPs (196.0 nm) and
TCAD@Ce6 NPs (160.0 nm) in the range of 50–200 nm (Fig. S3
(A), ESI† and 2A, insert) indicated that TCAD NPs and
TCAD@Ce6 NPs may preferentially distribute into the tumor
by the enhanced permeability and retention (EPR) effect.38,39
The morphology of the dried TCAD NPs and TCAD@Ce6 NPs
was evaluated by transmission electron microscopy (TEM). The
TEM image results proved that the TCAD NPs and TCAD@Ce6
NPs were almost spherical and uniform with good mono-
dispersity (Fig. 2A and S2(B), ESI†). Moreover, the scanning elec-
tron microscopy (SEM) imaging of TCAD NPs showed a similar
result to TEM (Fig. S3(C), ESI†). The size of TCAD@Ce6 NPs
was smaller than TCAD NPs that may be owing to the addition
of Ce6, which increases the hydrophobic interaction during
the self-assembly process. More importantly, the results of the
hydrodynamic diameter measured at fixed time points for a
month indicated that the sizes of TCAD NPs and TCAD@Ce6
NPs fluctuate in a small scope, suggesting that both TCAD NPs
and TCAD@Ce6 NPs are stable and can be stored in water for
relatively long periods of time without sedimentation or aggre-
gation (Fig. 2B). The critical aggregation concentrations (CACs)
of TCAD NPs were determined by using pyrene as the fluo-
rescent probe.40 In detail, the CACs of micelles were related to
the emission intensity ratio of the third and first bands (I3/I1)
in the fluorescence spectrum of pyrene. The value of CAC was
assessed from the first inflection point in the curve of the
absorption intensity ratio of I3/I1 versus the logarithm of con-
centration.41 The CAC value of TCAD NPs was calculated to be
23.4 µg mL−1 approximately (Fig. S4, ESI†).
In vitro DOX and Ce6 release
To demonstrate the acid-sensitivity of TCAD@Ce6 NPs, the
in vitro DOX and Ce6 release behavior of TCAD@Ce6 NPs was
measured by dialysis in PBS at pH 7.4, 6.5, and 5.5 at 37 °C,
respectively. The results of cumulative release curves revealed
DOX and Ce6 without significant burst release from
TCAD@Ce6 NPs in PBS (pH 7.4), suggesting a good stability of
TCAD@Ce6 NPs under normal physiological tissue conditions
(Fig. 2C). Nevertheless, at mild acidic environmental pH 6.5 or
even 5.5, which simulated the tumor tissular and intracellular
microenvironment, respectively, the cumulative release of
DOX and Ce6 was accelerated dramatically. When incubated
with PBS (pH = 5.5), the cumulative release of DOX and Ce6
from the TCAD@Ce6 NPs was higher than that observed when
incubated with PBS (pH = 6.5). On this basis, the TCAD@Ce6
NPs will release more of their drug cargo in the endo/lyso-
somal vesicles (pH 5.5) than in the solid tumor extracellular
environment (pH 6.5). Moreover, most of the TCAD@Ce6 NPs
may be taken up by the tumor cells before releasing their drug
cargo. In this case, even if some of the drug cargo were
released in the solid tumor extracellular environment they may
enter the tumor cells by passive diffusion, which may have
little influence on cellular uptake and therapeutic efficacy.42,43
All the results may be attributed to the expedited hydrolysis of
Fig. 2 Characterization of the nanoprobes. (A) Morphology of TCAD@Ce6 NPs observed by TEM and size distribution measured by DLS; (B) colloid
stability test of TCAD and TCAD@Ce6 NPs in water; (C) cumulative release DOX and Ce6 from TCAD@Ce6 NPs at different pH; (D) the NIR image of
TCAD@Ce6 NPs in culture medium (10% FBS) without cells (M) or co-incubated with A549 cells (M + C) for different times.
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the acid-sensitive linker in an acidic environment. This acid-
sensitive release of TCAD@Ce6 NPs makes them an interesting
tool for clinical tumor chemo–photodynamic combination
therapy that may minimize the damage of healthy tissues and
maximize the therapeutic efficacy. The Ce6 was wrapped into
the interior of TCAD@Ce6 NPs, which might cause the aggre-
gation of Ce6 by π–π and hydrophobic interactions, resulting
in a dramatic reduction of NIR fluorescence by self-quenching.
That is, the recovery of NIR fluorescence of Ce6 from
TCAD@Ce6 NPs can be correlated with the release of Ce6. To
estimate the intracellular NIR fluorescence recovery of Ce6 in
TCAD@Ce6 NPs, the NIR fluorescence images of TCAD@Ce6
NPs after co-incubation with or without A549 cells at different
time points were analysed (Fig. 2D). In the absence of A549
cells, the fluorescence changed little in the medium over time.
Noteworthily, the fluorescence intensity increased dramatically
with the extending of the incubation time in the presence of
A549 cells, suggesting that the Ce6 was gradually released from
TCAD@Ce6 NPs inside the cell, resulting in the fluorescence
recovery of Ce6. Moreover, the fluorescence of Ce6 in the
TCAD@Ce6 NPs was dramatically lower than free Ce6 due to
the self-quenching effect before being treated with mild acidic
PBS (pH = 5.5). However, after 24 h incubation in mild acidic
PBS (pH = 5.5), an obvious increase of the fluorescence inten-
sity of Ce6 was detected (Fig. S5, ESI†). Therefore, we came to
a conclusion that the acid-sensitive TCAD@Ce6 NPs would
self-quench the phototoxicity in blood circulation to weaken
the side effects and recover phototoxicity in the target tumor
acid microenvironment.
Cellular uptake and intracellular distribution
The cellular uptake behavior of TCAD and TCAD@Ce6 nano-
particles was evaluated by confocal laser scanning microscopy
(CLSM) and flow cytometry (FCM) toward A549 cells. Flow cyto-
metry analysis after 4 h incubation (Fig. 3A and B) indicated
that about 21.5% of A549 cells displayed a fluorescence signal
from DOX in TCAD NPs, which is higher than that detected in
free DOX (about 15.5%). However, after 12 hours incubation,
the same analysis revealed that the ratio of A549 cells with the
fluorescence signal of DOX when exposed to TCAD NPs was
Fig. 3 Cellular uptake efficacy and localization. Flow cytometry separate analysis (A) and integral analysis (B) of cellular uptake of free Ce6, free
DOX, TCAD and TCAD@Ce6 NPs for 4 h and 12 h, respectively; (C) confocal images of A549 cells exposed to free Ce6 or TCAD@Ce6 NPs for 4 h and
12 h, respectively. Scale bar, 100 μm.
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increased to about 92.7%, which was higher than that of free
DOX (about 64.1%). Meanwhile, the fluorescence signal inten-
sity of DOX from TCAD NPs was similar to that of TCAD@Ce6
NPs in A549 cells with prolonged incubation time. Predictably,
the cells co-cultured with TCAD@Ce6 for 4 h or 12 h exhibited
significantly higher ratios of Ce6 fluorescence signal when
compared to those incubated with free Ce6. It demonstrated
that TCAD@Ce6 NPs would enhance the cellular uptake capa-
bility of Ce6 and DOX in A549 cells, compared with free Ce6
and free DOX. Overall, these phenomena may be due to the
efficient endocytosis and rapid intracellular DOX and Ce6
release, which were induced by the intracellular acidic micro-
environment-triggered hydrolysis of the amide linker in TCAD
and TCAD@Ce6.44
DOX is a well known and widely used anticancer drug that
shows the anti-cancer effect by damaging the DNA structure in
nuclei.45 Whereas Ce6, a common photosensitizer, tends to
locate in the cytoplasm.46 Next, TCAD NPs and TCAD@Ce6
NPs were incubated with A549 cells for 4 h and 12 h, respecti-
vely. Confocal microscopy images were utilized to visually
show the cellular internalization and the intracellular release
of DOX and Ce6. As shown in Fig. 3C, the green fluorescence
and red fluorescence were used to localize the DOX and Ce6,
respectively. Hoechst 33342 was used to stain the nuclei (blue).
For free DOX, after being incubated with A549 cells for 4 h,
very slight green fluorescence was detected, suggesting that
free DOX entered the cells at low quantities. When incubation
times were prolonged to 12 h, the green fluorescence of free
DOX was spread all over the cells and the intensity of green
fluorescence was enhanced (Fig. S6, ESI†). In contrast, in the
case of TCAD NPs and TCAD@Ce6 NPs, DOX was observed to
be highly accumulated in nuclei compared with free DOX,
when incubated with A549 cells for 4 h (Fig. S6† and 3C).
Meanwhile, a significant increase of the green fluorescence
intensity of DOX in nuclei was detected, after TCAD NPs and
TCAD@Ce6 NPs were incubated with A549 cells for 12 h.
These observations demonstrated that TCAD NPs may be an
attractive way to help DOX circumvent the multidrug resist-
ance, enter into the cytoplasm and then diffuse into the
nucleus. Additionally, the red fluorescence intensity of Ce6 in
the cytoplasm from the TCAD@Ce6 NPs was higher than that
of free Ce6, and increased remarkably with the extension of
incubation time. In a word, the confocal microscopy images
obtained are consistent with the results obtained by flow cyto-
metry. The enhanced cell uptake of TCAD NPs and TCAD@Ce6
NPs may take advantage of endocytosis efficiently rather than
passive diffusion through the cell membrane of free DOX and
free Ce6.47
In vitro cellular toxicity
MTT assay was executed to detect the in vitro cellular prolifer-
ation inhibition of free DOX, and TCAD NPs against A549
cells. As shown in Fig. 4A, TCAD NPs exhibited more notable
antiproliferation efficacy on A549 cells in vitro than that of
equivalent free DOX, after 24 h or 48 h co-incubation. The
trends became more significant with the increasing incubation
time. The result was also verified by the apoptosis assay
(Fig. 4B). These may take advantage of the cellular uptake
enhancement of TCAD NPs and the quick release of DOX in
the acidic intracellular microenvironment as demonstrated
above.
Singlet oxygen would induce the damage of cellular con-
stituents and subsequent cell death, which can denote the
phototoxicity of nanoparticles.20 The extracellular singlet
oxygen production was detected by a singlet oxygen sensor
green (SOSG) reagent. TCAD@Ce6 NPs exhibited the increased
singlet oxygen generation capability along with prolongation
of irradiation time (Fig. S7, ESI†). Moreover, the DCFH-DA
staining method was employed to examine the intracellular
singlet oxygen production for actual research on the photo-
toxicity of intracellular nanoparticles. As expected, detected by
the flow cytometry assay, the TCAD@Ce6 NPs caused the most
remarkable singlet oxygen production under irradiation com-
pared with free Ce6 under irradiation and TCAD@Ce6 NPs
without irradiation (Fig. S8, ESI†). Subsequently, the cytotoxic
efficacy and the efficiency of chemo–photodynamic combi-
nation therapy of TCAD@Ce6 NPs to A549 cells with or
without laser irradiation was further quantified by MTT assay
and apoptosis assay. As shown in Fig. 4C, compared to treat-
ment with free Ce6/laser, a significantly decreased survival
ratio of A549 cells was detected when treated with TCAD@Ce6
NP/laser. In addition, after 24 h incubation, the survival ratio
of A549 cells was 71.2% and 66.44% when treated with free
Ce6 (4.0 µg mL−1) upon laser irradiation for 3 min (Fig. 4C)
and TCAD NPs (equivalent DOX 6.0 µg mL−1) (Fig. 4A),
respectively, while the cell survival ratio of A549 cells suddenly
decreased to 15.73% when exposed to TCAD@Ce6 NPs (equi-
valent Ce6 4.0 µg mL−1 and equivalent DOX 5.86 µg mL−1)
plus laser irradiation for 3 min (Fig. 4C). That is, with the
same concentrations of Ce6 plus laser irradiation or DOX, the
TCAD@Ce6 NPs would lead to the mortality rate as high as
about 2.9 times that treated with the free Ce6, and about 2.5
times higher than that treated with TCAD NPs. All the results
indicated that the combination therapy resulted in a more
striking tumor treatment effect than chemo or photodynamic
treatment alone.
The flow cytometry assay reconfirmed that minimal apopto-
sis and necrosis of A549 cells (mortality ratio <11%) were
induced by free Ce6 in the dark or cells with only laser
exposure. Meanwhile, the ratio of apoptosis and necrosis was
increased to 80% when the cells were exposed to TCAD@Ce6
NPs plus laser irradiation, while a slight increase in cell apop-
tosis was detected when treated with free Ce6 plus laser
irradiation (Fig. 4D). Furthermore, the cell was stained with
Calcein-AM and PI to visually detect the photodamage, when
cultured with free Ce6 and TCAD@Ce6 NPs with or without a
laser. The red fluorescence of PI and the green fluorescence of
Calcein-AM were on the behalf of dead and live cells, respecti-
vely. As anticipated, after 3 min of irradiation, there was weak
red fluorescence emitted from the cells treated with free Ce6,
suggesting that little cells were photodamaged (Fig. 4E). The
low cellular uptake and the little intracellular singlet oxygen
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production may be the likely reason. Nevertheless, the
TCAD@Ce6 NP treated cells showed striking red fluorescence
signals with laser irradiation. That is, the phototoxicity of
TCAD@Ce6 NPs is higher than free Ce6 upon the NIR laser
irradiation. The experimental results of the singlet oxygen
detection test, MTT assay, apoptosis assay and Calcein-AM and
PI staining assay were consistent, revealing that TCAD@Ce6
NPs may be a promising way for DOX delivery and PDT
treatment.
Tumor-targeting evaluation of the TCAD@Ce6
The intrinsic NIR fluorescence of Ce6 allows the detection of
the tumor targeting and in vivo distribution of TCAD@Ce6 NPs
in A549 tumor-bearing nude mice by the NIR imaging
approach. The Ce6 and TCAD@Ce6 NPs were tail vein injected
into the A549 tumor-bearing nude mice to monitor their time
dependent distribution in vivo. As shown in Fig. 5A, free Ce6
as a kind of small dye molecule, in the absence of tumor tar-
geting, mainly accumulated in the liver and was rapidly catabo-
lized from mice, whereas the TCAD@Ce6 NPs exhibited
relatively high tumor targeting efficiency and relatively long
tumor retention time. That is TCAD@Ce6 NPs for PDT would
prolong the phototoxicity duration and enhance the tumor
accumulation of Ce6. More importantly, despite a strong NIR
fluorescence signal was observed in the liver after 2 h injec-
tion, the tumor site of TCAD@Ce6 NP treated mice exerted a
higher NIR fluorescence than free Ce6 treated ones. As the
time goes on, the accumulation of fluorescence signals was
gradually reduced in the liver while it gradually increased in
the tumor. The fluorescence intensity signals of tumors
reached a maximum at 12 h post-injection and with a slight
decrease after 24 h injection, suggesting that the TCAD@Ce6
NPs were not subject to rapid metabolism from mice and were
excellently in vivo tumor-specific by the EPR effect. Further-
more, the mean fluorescence intensity of tumors treated with
TCAD@Ce6 NPs and free Ce6 was quantified (Fig. 5B). The
fluorescence accumulation in the tumors of Ce6 in TCAD@Ce6
NPs was about 18 fold higher than free Ce6, 12 h post-injection.
Fig. 4 In vitro cellular toxicity. MTT assay quantitative evaluation (A) and flow cytometry analysis (B) of cell survival for A549 cells treated with free
DOX and TCAD NPs for 24 h and 48 h, respectively; dark toxicity and photocytoxicity of free Ce6 and TCAD@Ce6 NPs towards A549 cells for 24 h,
analyzed by the MTT assay (C) and flow cytometry (D), respectively; (E) detection of photodamage by fluorescence microscopy using fluorescent
probes (double-staining with calcein PI and calcein-M). Dead cells: red fluorescence of PI, live cells: green fluorescence of calcein-AM. The data are
shown as mean ± SD (n = 3).
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In addition, in vitro fluorescence images of organs (heart,
liver, spleen, lung, and kidney) excised from mice (sacrificed at
24 h post-injection) were obtained to intuitively observe the
tumor targeting efficacy and tissue distribution of free Ce6 and
TCAD@Ce6 NPs. Predictably, similar to the in vivo images,
TCAD@Ce6 NPs were much more inclined to accumulate to
tumors than to stay in normal organs, indicating that they may
possess high therapeutic efficiency and low side effects for
PDT (Fig. 5C). Nevertheless, the fluorescence of free
Ce6 mainly remained in the liver. Similar to free DOX, the
TCAD@Ce6 NPs were mainly captured and metabolized by the
liver and kidney, resulting in strong fluorescence signals of
TCAD@Ce6 NPs in the liver and kidney.4 The mean fluo-
rescence intensity of organs and tumors was also quantified
(Fig. 5D).
Photodynamic therapeutic efficacy of TCAD@Ce6 NPs in
tumor-bearing mice
To evaluate the chemo–photodynamic therapeutic efficacy of
TCAD@Ce6 NPs in vivo, phosphate buffer solution (PBS), free
DOX, TCAD NPs, free Ce6 and TCAD@Ce6 NPs were intra-
venously injected into A549 tumor-bearing mice when the
tumor size grew to 90–100 mm3. To monitor the photodynamic
therapeutic efficacy, the tumor sites of free Ce6 and
TCAD@Ce6 NP treated mice were irradiated with a NIR laser
(633 nm, 50 mW cm−2) for 30 min, after 12 h injection. As
shown in Fig. S9,† at 4 days post-irradiation, TCAD@Ce6 NPs
plus laser treated mice showed slight hemorrhagic injury at
the irradiation tumor site, while the free Ce6/laser or PBS/laser
treated group has no noticeable phototoxicity damage. After 14
days, normal tissue had already regenerated at the necrotic
scar site of tumors. The change of the tumor volume and body
weight of tumor-bearing mice was monitored every 3 days
within 18 days. As shown in Fig. 6A, NIR laser irradiation may
not significantly inhibit the A549 tumor growth, when A549
tumor-bearing mice were treated with saline. Because of the
short blood circulation time and less tumor accumulation of
free Ce6, the growth of the tumor tissue of free Ce6 treated
mice was not successfully suppressed. Importantly, the tumor
was repressed by the singlet oxygen generated by TCAD@Ce6
NPs upon irradiation that is not present in TCAD NPs. It must
be acknowledged that the combined TCAD@Ce6/laser treat-
ment was remarkably more efficient in suppressing tumor
growth than treatment with free Ce6/laser or TCAD NPs.
Unlike free Ce6 or TCAD NPs alone, this observation may be
caused by the long retention time and tumor targeting efficacy
of TCAD@Ce6 NPs, where the tumor was inhibited by the com-
bination of chemo and photodynamic therapy effects. More-
over, the tumor inhibition efficacy of TCAD NPs and free DOX
was significantly different, which may be attributed to the
Fig. 5 In vivo fluorescence imaging and biodistribution of Ce6 and TCAD@Ce6 NPs. (A) In vivo time-dependent whole body fluorescence imaging
of A549 tumor-bearing mice after intravenous injection of free Ce6 or TCAD@Ce6 NPs; (B) quantification of average fluorescence signals in the
tumor site of (A). (C) In vitro fluorescence images of major organs and tumors of mice after intravenous injection of free Ce6 or TCAD@Ce6 NPs over
a period of 24 h; (D) quantification of average fluorescence signals of (C). The data are shown as mean ± SD (n = 3).
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efficient tumor accumulation of acid-sensitive TCAD by the
EPR effect and quick excretion by glomerular filtration of free
DOX.5 Interestingly, TCAD@Ce6 NPs with laser irradiation,
with an efficient combination of Ce6-mediated phototoxicity
and DOX-mediated chemotherapy, led to effective inhibition
of tumor growth with the average tumor volume of 95.29%
smaller than that of the saline control mice 18 days post-
irradiation. All the results confirm the superiority of the
chemo–photodynamic combined therapy of TCAD@Ce6 NPs.
As we all know, the body weight of the mouse can indicate the
treatment-induced toxicity. As shown in Fig. 6B, the body
weight loss of mice treated with TCAD NPs was relatively slight
compared to those treated with free DOX which had an
obvious weight loss. This revealed that the TCAD NPs are a
relatively safe prodrug for tumor therapy. Meanwhile, no sig-
nificant variation of body weight was observed after treatment,
indicating that the chemo–photodynamic therapy of
TCAD@Ce6 NPs may hardly induce treatment toxicity. More-
over, haematoxylin and eosin (H&E) staining of organs was exe-
cuted for histopathological examination. As expected, the
TCAD@Ce6 NP groups showed neither obvious pathological
abnormality or lesion in the heart, spleen, and kidney nor
obvious liver damage (Fig. S10†). Overall, the combination
treatment of TCAD@Ce6 NPs upon laser irradiation demon-
strated remarkable anticancer efficacy with little side effects.
Conclusions
In summary, we successfully prepared novel well-defined acid-
sensitive TCAD@Ce6 NPs by a self-assembly process for tumor
NIR imaging and chemo–photodynamic combination therapy.
The TCAD@Ce6 NPs exhibited stability in water and could be
easily hydrolyzed in the acidic microenvironment of tumors.
Compared with free Ce6 and DOX, it could significantly
enhance the cellular uptake of DOX and Ce6 and induce
higher phototoxicity upon NIR laser irradiation. Based on the
EPR effect, TCAD@Ce6 NPs could accumulate in tumor sites
effectively for tumor NIR fluorescence imaging and efficient
inhibition of the growth of A549 tumors under laser
irradiation in vivo. High performance TCAD@Ce6 NPs can
serve as prodrugs for DOX delivery and specific combined
chemo–photodynamic therapy, and exhibit great potential in
applications such as tumor NIR fluorescence imaging and sim-
ultaneous combined chemo–photodynamic therapy in the
near future.
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